USANA Health Sciences (NYSE: USNA) reported Q4 EPS of $0.60, $0.20 better than the analyst estimate of $0.40. Revenue for the quarter came in at $226.2 million versus the consensus estimate of $220.79 million.

GUIDANCE:

USANA Health Sciences sees FY2026 EPS of $1.95-$2.29, versus the consensus of $1.84. USANA Health Sciences sees FY2026 revenue of $0.92-1 billion, versus the consensus of $0.95 billion.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.